Search for: "C. G., Matter of" Results 601 - 620 of 3,571
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Mar 2011, 3:01 pm by Oliver G. Randl
According to the established case law of the Boards of appeal a claim falls under the exclusion from patentability pursuant to A 53 c) even if part of the claimed subject-matter is a method for treatment of the human or animal body by therapy (G 1/04 [6.2.1], confirmed by G 1/07 [3.2] and G 1/08 (sic) [5.6]). [read post]
7 Jul 2017, 3:40 pm by Jacob Sapochnick
The press release outlines who will not be affected by the travel ban as follows: The Executive Order’s Travel Restrictions do not apply to: (a) Lawful permanent residents; (b) Any foreign national admitted to or paroled into the United States on or after June 26, 2017; (c) Non-Immigrant visa classifications: A-1, A-2, NATO 1 though NATO 6, C-2, C-3, G-1, G-2, G-3, and G-4; (d) Any foreign national who has been granted… [read post]
1 Oct 2022, 2:31 pm by Lawrence B. Ebert
Section 103(c)(1) (pre-AIA) provides that “[s]ubject matter developed by another person, which qualifies as prior art only under one or more subsections (e), (f), and (g) of section 102, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the claimed invention was made, owned by the same person or subject to an obligation of assignment to the same person. [read post]
24 Apr 2011, 2:44 pm by Adam B. Cordover, Attorney-at-Law
Petersburg and Clearwater family law sections, except as provided herein, all post judgment matters and temporary support matters are automatically referred to mediation. [read post]
15 Sep 2019, 7:10 pm by Omar Ha-Redeye
Not too long before Bill C-75, the federal government passed Bill C-46, coming into effect in December 2018. [read post]
18 Jan 2019, 4:42 am by Jessica Kroeze
 Relying inter alia on T 990/96, the Examining Division argued that the disclosure of amorphous Lercanidipine Hydrochloride ("LH") and its manufacture in prior art document D1 already had made available this compound to the public in the sense of Article 54 EPC in all desired grades of purity, and the claimed degree of purity could therefore not render the claims novel.Departing from T 990/96 and subsequent cases including T 0728/98, the present… [read post]
6 Aug 2013, 5:01 pm by oliver randl
In decision T 604/01, the board held that objections under A 123(2) and (3) which the opponent raised during the opposition proceedings but did not further explain until OPs could not be excluded under R 71a(1) EPC 1973 because these objections were a matter of argument. [read post]
27 Jan 2014, 2:03 pm
Furthermore, 11 NYCRR 65-3.5(c) entitles an insurer to receive all items necessary to verify a claim directly from the parties from whom such verification was requested. [read post]
20 Apr 2015, 4:23 pm by Kenneth Vercammen Esq. Edison
Subsection (g) was inserted in connection with the decision to abandon the effort to describe ancillary administration in Article IV. [read post]
5 Oct 2017, 2:07 pm by Daphne Keller
The section 512(g) counter-notification process refers only to 512(c) hosting providers, not other OSPs (e.g., search engines), for starters. [read post]
6 Oct 2020, 7:55 am by Courtenay C. Brinckerhoff
  A method for immunomodulation or treating a viral condition[ ], a viral disease, cancers or tumors comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of a composition comprising: a recombinant polypeptide produced by a non-human host transformed by a recombinant DNA molecule comprising a DNA sequence selected from the group consisting of: (a) DNA sequences which are capable of hybridizing to any of the DNA inserts of… [read post]
19 May 2024, 10:27 pm by Marcel Pemsel
It will be interesting to see what the appointed Advocate General has to say and how the CJEU decides the matter. [read post]